POLYMORPHIC DELETIONS OF GLUTATHIONE S-TRANSFERASES M1, T1 AND BLADDER CANCER RISK IN ALGERIAN POPULATION

Ahmed Hireche; Naouel Chaoui Kherouatou; Asma Ribouh; Noureldine Abadi; Ming Jun Shi; Dalila Satta

doi:10.22159/ajpcr.2018.v11i5.25673

Authors

Ahmed Hireche Department of Animal Biology, Laboratory of Cellular and Molecular Biology, University Constantine 1, Constantine 25000, Algeria.
Naouel Chaoui Kherouatou Department of Animal Biology, Laboratory of Cellular and Molecular Biology, University Constantine 1, Constantine 25000, Algeria.
Asma Ribouh Department of Animal Biology, Laboratory of Cellular and Molecular Biology, University Constantine 1, Constantine 25000, Algeria.
Noureldine Abadi Laboratory of Biology and Molecular Genetic, University Constantine 3, Constantine 25000, Algeria.
Ming Jun Shi Laboratory of Molecular Oncology, UMR 144, Institut Curie, 75005 Paris, France.
Dalila Satta Department of Animal Biology, Laboratory of Cellular and Molecular Biology, University Constantine 1, Constantine 25000, Algeria.

DOI:

https://doi.org/10.22159/ajpcr.2018.v11i5.25673

Keywords:

Glutathione S-transferase mu 1, Glutathione S-transferase theta 1, Smoking, Bladder cancer

Abstract

Objective: Glutathione S-transferase mu 1 (GSTM1) and GST theta 1 (GSTT1) genes are two xenobiotic metabolizing genes in Phase II of the detoxification process. The polymorphisms of GSTM1, GSTT1 genes, and smoking are involved in many cancers such as bladder cancer. Our aim was to assess the role of smoking status and GSTM1 and GSTT1 null genotypes in bladder cancer development in Algerian population.

Methods: The current caseâ€“control study included 175 bladder cancer patients and 188 controls matched for age, gender, and ethnic origin. The GSTM1 and GSTT1 genotypes were determined by multiplex polymerase chain reaction using blood genomic DNA. Possible associations of stage and grade with the obtained genotypes were also tested.

Results: A significant associations were observed between bladder cancer risk and tobacco smoke (p value: p=1.21E-08), GSTM1 null genotype (p=0.018), GSTT1 null genotype (p=0.009), and GSTM1/GSTT1-double null genotype (p=0.001). The combined effect of smoking and testing deletions increased the risk of bladder cancer and the most important risk was observed among smokers carrying GSTM1/GSTT1-double null genotype (p=1.09E-05). No significant association was shown between stage and grade of bladder cancer and the testing genotypes.

Conclusion: This study indicated that smoking, GSTM1 null, GSTT1 null, and GSTM1/GSTT1-double null genotypes individually represent a risk factor for bladder cancer in Algerian population. The interaction smoking gene increased the risk considerably. In fact, it is suggested that patients with cigarette smoking habit and combined GSTM1 and T1 genes deletion might be at increased risk of bladder cancer.

Downloads

Download data is not yet available.

References

Saka S, Singh AN, Sharma N. Potential anti-cancer superfoods: A minireview. Int J Curr Pharm Res 2016;8:19-21.

Gupta M, Dahiya J, Marwaha RK, Dureja H. Therapies in cancer treatment: An overview. Int J Pharm Pharm Sci 2015;7:1-9.

Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base 2013. Available from: http://globocan.iarc.fr/. [Last accessed on 2016 may 30].

Hamdi Cherif M, Serraino D, Mahnane A, Laouamri S, Zaidi Z, Boukharouba H, et al. Time trends of cancer incidence in Setif, Algeria, 1986-2010: An observational study. BMC Cancer 2014;14:637.

Freedman ND, Silverman DT, Hollenbeck AR, Schatzkin A, Abnet CC. Association between smoking and risk of bladder cancer among men and women. JAMA 2011;306:737-45.

Ferris J, Garcia J, Berbel O, Ortega J A. Constitutional and occupational risk factors associated with bladder cancer. Actas Urol Esp 2013;37:513- 22.

Kiriluk KJ, Prasad SM, Patel AR, Steinberg GD, Smith ND. Bladder cancer risk from occupational and environmental exposures. Urol Oncol 2012;30:199-211.

Burger M, Catto JW, Dalbagni G, Grossman HB, Herr H, Karakiewicz P, et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol 2013;63:234-41.

Matic M, Pekmezovic T, Djukic T, Mimic-Oka J, Dragicevic D, Krivic B, et al. GSTA1, GSTM1, GSTP1, and GSTT1 polymorphisms and susceptibility to smoking-related bladder cancer: A case-control study. Urol Oncol 2013;31:1184-92.

Mitra AP, Cote RJ. Molecular pathogenesis and diagnostics of bladder cancer. Annu Rev Pathol 2009;4:251-85.

Safarinejad MR, Safarinejad S, Shafiei N, Safarinejad S. Association of genetic polymorphism of glutathione S-transferase (GSTM1, GSTT1, GSTP1) with bladder cancer susceptibility. Urol Oncol 2013;31:1193- 203.

Abd El Hameed AH, Negm OE, El-Gamal OM, Hamouda HE, El Nouby KA, Ismail GM, et al. Genetic polymorphism of glutathione S-transferases M1 and T1 in egyptian patients with bilharzial bladder cancer. Urol Oncol 2010;28:296-301.

Song DK, Xing DL, Zhang LR, Li ZX, Liu J, Qiao BP, et al. Association of NAT2, GSTM1, GSTT1, CYP2A6, and CYP2A13 gene polymorphisms with susceptibility and clinicopathologic characteristics of bladder cancer in central china. Cancer Detect Prev 2009;32:416-23.

Coles BF, Morel F, Rauch C, Huber WW, Yang M, Teitel CH, et al. Effect of polymorphism in the human glutathione S-transferase A1 promoter on hepatic GSTA1 and GSTA2 expression. Pharmacogenetics 2001;11:663-9.

Khan AR, Taneja P. Cationic peptide lactoferricin B inhibits glutathione S-transferase P1 from human placenta and breast cancer cell line MDA-MB-231 preventing anticancer drog antimetabolism. Int J Pharm Pharm Sci 2015;7:238-41.

Malik SS, Nawaz G, Masood N. Genotypes of GSTM1 and GSTT1: Useful determinants for clinical outcome of bladder cancer in Pakistani population. Egypt J Med Hum Genet 2016. DOI:10.1016/j. ejmhg.2016.03.001.

Brennan P, Bogillot O, Cordier S, Greiser E, Schill W, Vineis P, et al. Cigarette smoking and bladder cancer in men: A pooled analysis of 11 case-control studies. Int J Cancer 2000;86:289-94.

Altayli E, Gunes S, Yilmaz AF, Goktas S, Bek Y. CYP1A2, CYP2D6, GSTM1, GSTP1, and GSTT1 gene polymorphisms in patients with bladder cancer in a turkish population. Int Urol Nephrol 2009;41:259- 66.

Gong M, Dong W, An R. Glutathione S-transferase T1 polymorphism contributes to bladder cancer risk: A meta-analysis involving 50 studies. DNA Cell Biol 2012;31:1187-97.

Henriquez-Hernandez LA, Navarro P, Luzardo OP, Alvarez-Leon EE, Boarda LD, Zumbado M. Polymorphisms of glutathione S-transferase mu and theta, MDR1 and VEGF genes as risk factors of bladder cancer: A case-control study. Urol Oncol 2012;30:660-5.

Lin HJ, Han CY, Bernstein DA, Hsiao W, Lin BK, Hardy S, et al. Ethnic distribution of the glutathione transferase mu 1-1 (GSTM1) null genotype in 1473 individuals and application to bladder cancer susceptibility. Carcinogenesis 1994;15:1077-81.

Rouissi K, Ouerhani S, Oliveira E, Marrakchi R, Cherni L, Ben Othman F, et al. Polymorphisms in one-carbon metabolism pathway genes and risk for bladder cancer in a Tunisian population. Cancer Genet Cytogenet 2009;195:43-53.

Fatma B, Aida T, Maurice JA, Saguem S. Glutathione S-transferase M1 and T1, CYP1A2-2467T/delT polymorphisms and non small-cell lung cancer risk in Tunisian sample. Egypt J Med Hum Genet 2012;13:307- 12.

Goerlitz D, El Daly M, Abdel-Hamid M, Saleh DA, Goldman L, El Kafrawy S, et al. GSTM1, GSTT1 null variants, and GPX1 single nucleotide polymorphism are not associated with bladder cancer risk in Egypt. Cancer Epidemiol Biomarkers Prev 2011;20:1552-4.

Nelson HH, Wiencke JK, Christiani DC, Cheng TJ, Zuo ZF, Schwartz BS, et al. Ethnic differences in the prevalence of the homozygous deleted genotype of glutathione S-transferase theta. Carcinogenesis 1995;16:1243-5.

Zhang R, Xu G, Chen W, Zhang W. Genetic polymorphisms of glutathione S-transferase M1 and bladder cancer risk: A meta-analysis of 26 studies. Mol Biol Rep 2011;38:2491-7.

Sharma N, Singh A, Singh N, Behera D, Sharma S. Genetic polymorphisms in GSTM1, GSTT1 and GSTP1 genes and risk of lung cancer in a north indian population. Cancer Epidemiol 2015;39:947-55.

Rouissi K, Ouerhani S, Marrakchi R, Ben Slama MR, Sfaxi M, Ayed M, et al. Combined effect of smoking and inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1 on bladder cancer in a Tunisian population. Cancer Genet Cytogenet 2009;190:101-7.

Rouissi K, Ouerhani S, Hamrita B, Bougatef K, Marrakchi R, Cherif M, et al. Smoking and polymorphisms in xenobiotic metabolism and DNA repair genes are additive risk factors affecting bladder cancer in northern Tunisia. Pathol Oncol Res 2011;17:879-86.

Saad AA, Oâ€™Connor PJ, Mostafa MH, Metwalli NE, Cooper DP, Povey AC, et al. Glutathione S-transferase M1, T1 and P1 polymorphisms and bladder cancer risk in Egyptians. Int J Biol Markers 2005;20:69-72.

Anwar WA, Abdel-Rahman SZ, El-Zein RA, Mostafa HM, Au WW. Genetic polymorphism of GSTM1, CYP2E1 and CYP2D6 in Egyptian bladder cancer patients. Carcinogenesis 1996;17:1923-9.

Kang HW, Song PH, Ha YS, Kim WT, Kim YJ, Yun SJ, et al. Glutathione S-transferase M1 and T1 polymorphisms: Susceptibility and outcomes in muscle invasive bladder cancer patients. Eur J Cancer 2013;49:3010-9.